Cargando…

Genetically proxied therapeutic prolyl-hydroxylase inhibition and cardiovascular risk

Prolyl hydroxylase (PHD) inhibitors are in clinical development for anaemia in chronic kidney disease. Epidemiological studies have reported conflicting results regarding safety of long-term therapeutic haemoglobin (Hgb) rises through PHD inhibition on risk of cardiovascular disease. Genetic variati...

Descripción completa

Detalles Bibliográficos
Autores principales: Harlow, Charli E, Patel, Vickas V, Waterworth, Dawn M, Wood, Andrew R, Beaumont, Robin N, Ruth, Katherine S, Tyrrell, Jessica, Oguro-Ando, Asami, Chu, Audrey Y, Frayling, Timothy M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9851745/
https://www.ncbi.nlm.nih.gov/pubmed/36048866
http://dx.doi.org/10.1093/hmg/ddac215